We are excited to announce that our collaboration with the FDA Center for Biologics Evaluation and Research (CBER) to develop a standardized Neisseria gonorrhoeae serum bactericidal assay and complement source has been pre-published. We hope this helps drive the bacterial vaccine field forward.
The paper, Development and validation of a standardized human complement serum bactericidal activity assay to measure functional antibody responses to Neisseria gonorrhoeae (Matthias KA et al., Vaccine, 2025; doi:10.1016/j.vaccine.2024.126508), uses Pel-Freez IgG/IgM-depleted human complement.
Originally shared on LinkedIn.